Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ozarelix
- Development stage
- Phase 2
- Lead developer
- Ceapro
- Modality
- Peptides, Small Molecules
- Administration
- Injection (parenteral)
01
Overview
Ozarelix is a synthetic, highly modified fourth-generation linear decapeptide that acts as a gonadotropin-releasing hormone (GnRH) antagonist. It competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, leading to rapid inhibition of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. In males, this results in decreased testosterone production, which can be beneficial for treating hormonally dependent diseases such as prostate cancer and benign prostatic hyperplasia (BPH). Ozarelix was developed as a long-lasting injectable formulation primarily for prostate cancer but was also investigated for BPH, endometriosis, Alzheimer's disease, and ovarian cancer. Development has been discontinued or terminated for most indications[1][2][3][4][5].
- Other names
- ozarelixumOzarélixOzarelix [INN]Q1IF8M2YL3Q-1IF8M2YL3Q 1IF8M2YL3UNII-Q1IF8M2YL3UNII-Q-1IF8M2YL3UNII-Q 1IF8M2YL3Ac-D-Nal(2)-D-Phe(4Cl)-D-Pal(3)-Ser-NMe-Tyr-D-Hcit-Nle-Arg-Pro-D-Ala-NH2
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on ozarelix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ozarelix.